Stocks Health care SPTX
NASDAQ · Health careSeaport Therapeutics, Inc. (SPTX)
At September 30, 2026 it held $61.6M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 2, 2026.
Key facts about Seaport Therapeutics, Inc.
- Net worth
- Seaport Therapeutics, Inc. has a market value (market cap) of $1.2B at the latest share price, and shareholders' equity of $397.5M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 2, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Seaport Therapeutics, Inc.'s next report is expected around January 15, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Seaport Therapeutics, Inc. does
Seaport Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker SPTX.
Earnings: every quarter and the next report date
Latest SEC filings
What Seaport Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 2, 2026
- November 2, 2026
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 5, 2026Passive stake (5% or more) SCHEDULE 13G
- August 5, 2026Passive stake (5% or more) SCHEDULE 13G
- August 3, 2026
- August 3, 2026
- June 8, 2026
- June 8, 2026
- May 11, 2026Activist stake (5% or more) SCHEDULE 13D
Insider trades
What the people running Seaport Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $99.3K worth of shares on the open market in the last 90 days and sold none.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 3, 2026 | Torres DeniceDirector | Bought | 5,000 | $99.3K |
| June 22, 2026 | Hombach Robert J.Director | Boughtindirect | 13,000 | $235.8K |
| May 4, 2026 | PureTech Health plc10% owner | Exercised optionsindirect | 12,736,014 | - |
| May 4, 2026 | PureTech Health plc10% owner | Exercised optionsindirect | 2,681,265 | - |
| May 4, 2026 | PureTech Health plc10% owner | Exercised optionsindirect | 965,255 | - |
| May 4, 2026 | Loebel AntonyChief Medical Officer | Exercised options | 20,109 | - |
| May 4, 2026 | ARCH Venture Partners XII, LLC10% owner | Exercised optionsindirect | 2,513,686 | - |
| May 4, 2026 | ARCH Venture Partners XII, LLC10% owner | Exercised optionsindirect | 2,681,265 | - |
Who owns SPTX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| PureTech Health plc13G, passive with 2 related filers | 31.2% | August 14, 2026 |
| ARCH Venture Fund XII, L.P.13D, may seek influence with 6 related filers | 11.9% | May 6, 2026 |
| General Atlantic, L.P.13D, may seek influence with 13 related filers | 11.5% | May 11, 2026 |
| Zohar Daphne13G, passive | 9.1% | August 5, 2026 |
| Paul Steven M13G, passive | 6.3% | August 5, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 54 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| ARCH Venture Management, LLC | 6,294,951 | new |
| General Atlantic, L.P. | 6,101,582 | new |
| Sofinnova Investments, Inc. | 3,564,871 | new |
| Goldman Sachs Group Inc | 2,178,642 | new |
| Trv GP VI, LLC | 2,061,222 | new |
| Canada Pension Plan Investment Board | 1,975,791 | new |
| Jpmorgan Chase & Co | 1,815,845 | new |
| Foresite Capital Management VI LLC | 1,779,521 | new |
| Fmr LLC | 1,185,100 | new |
| Bellevue Group AG | 1,100,000 | new |
| Siren, L.L.C. | 1,095,316 | new |
| Jennison Associates LLC | 1,079,669 | new |
| RA Capital Management, L.P. | 700,000 | new |
| Vanguard Capital Management LLC | 599,217 | new |
| Woodline Partners LP | 586,345 | new |
| Perceptive Advisors LLC | 500,000 | new |
| Braidwell LP | 500,000 | new |
| Principal Financial Group Inc | 414,672 | new |
| Aberdeen Group plc | 310,355 | new |
| UBS Group AG | 279,184 | new |
Insiders
10 insiders reported holding 26,669,616 shares in total, about $584.7M at the last price.
| Holder | Shares |
|---|---|
| PureTech Health plc10% owner | 16,685,01316,685,013 held indirectly |
| ARCH Venture Partners XII, LLC10% owner | 6,294,9516,294,951 held indirectly |
| Healy JamesDirector | 2,731,5382,731,538 held indirectly |
| Paul Steven MDirector | 863,031 |
| Gladstein LanaGeneral Counsel | 33,515 |
| Loebel AntonyChief Medical Officer | 20,109 |
| Torres DeniceDirector | 18,40613,406 held indirectly |
| Hombach Robert J.Director | 13,00013,000 held indirectly |
| White LaurenChief Financial Officer | 6,7026,702 held indirectly |
| Chen Michael CunyuanChief Scientific Officer | 3,351 |
Questions about SPTX
What does Seaport Therapeutics, Inc. do?
Seaport Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as SPTX. Its shares trade on NASDAQ under the ticker SPTX.
What is Seaport Therapeutics, Inc.'s net worth?
Seaport Therapeutics, Inc. has a market value (market cap) of $1.2B at the latest share price, and shareholders' equity of $397.5M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
When did Seaport Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 2, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the insider trade from November 4, 2026.
When is Seaport Therapeutics, Inc.'s next earnings report?
Seaport Therapeutics, Inc.'s next report is expected around January 15, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare SPTX with
Follow SPTX
Get an email when Seaport Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Seaport Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.